Protein folding, protein homeostasis, and cancer

Chinese Journal of Cancer

Volumn 30, Issue 2, 2011, Pages 124-137

  van Drie, John H ^a  

^a Van Drie Research LLC   (United States)

Author keywords

Chaperones; Chemotherapy; Heat shock proteins; Proteasome; Protein folding; Proteostasis

Indexed keywords

BORTEZOMIB; CHAPERONE; HEAT SHOCK PROTEIN; IMATINIB; PROTEASOME; PROTEIN P53; UBIQUITIN; VON HIPPEL LINDAU PROTEIN;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; DNA DAMAGE; DRUG APPROVAL; DRUG EFFICACY; DRUG TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN MOTIF; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 79954546178     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.010.10162     Document Type: Review

References (61)

1. Varmus H. The new era in cancer research [J]. Science, 2006, 312 (5777):1162-1165.
2. Stehelin D, Varmus HE, Bishop JM, et al. DNA related to the transforming gene (s) of avian sarcoma viruses is present in normal avian DNA [J]. Nature, 1976,260(5547):170-173.
3. Chabner BA, Roberts TG Jr. Chemotherapy and the war on cancer [J]. Nat Rev Cancer, 2005,5(1):65-72.
4. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib) [J]. Cancer Invest, 2004, 22(2):304-311.
5. Messaoudi S, Peyrat JF, Brion JD, et al., Recent advances in Hsp90 inhibitors as antitumor agents [J]. Anticancer Agents Med Chem, 2008,8(7):761-782.
6. Whitesell L, Lindquist S. HSP90 and the chaperoning of cancer [J]. Nat Rev Cancer, 2005,5(10):761-772.
7. Hartl FU, Hayer-Hartl M. Converging concepts of protein folding in vitro and in vivo [J]. Nat Struct Biol, 2009,16(6):574-581.
8. Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution [J]. Nature, 1998,396(6709):336-342.
9. Wegele H, Müller L,Buchner J. Hsp70 and Hsp90-a relay team for protein folding [J]. Re. Physiol Biochem Pharmacol, 2004,151:1-44.
10. Balch WE, Morimoto RI, Dillin A, et al. Adapting proteostasis for disease intervention [J]. Science, 2008,319(5865):916-919.
11. Oppermann H, Levinson W, Bishop JM. A cellular protein that associates with the transforming protein of Rous sarcoma virus is also a heat-shock protein [J]. Proc Natl Acad Sci USA, 1981,78(2): 1067-1071.
12. Scott MD, Frydman J. Aberrant protein folding as the molecular basis of cancer [M]. Bross P, Gregersen N, eds. Methods in Molecular Biology, vol 232: Protein misfolding and disease: principles and protocols. Totowa, NJ: Humana Press, 2003:67-76.
13. Bullock AN, Fersht AR. Rescuing the function of mutant p53 [J]. Nat Rev Cancer, 2001,1(1):68-76.
14. Oren M. Regulation of the p53 tumor suppressor protein [J]. J Biol Chem, 1999,274(51):36031-36034.
15. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network [J]. Nature, 2000,408(6810):307-310.
16. Hanahan D, Weinberg R. The hallmarks of cancer [J]. Cell, 2000, 100(1):57-70.
17. Bishop JM. The molecular genetics of cancer [J]. Science, 1987, 235(4786):305-311.
18. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers [J]. Nature, 1998,396(6712):643-649.
19. Anfinsen C. Studies on the principles that govern the folding of protein chains. 1972 Nobel Prize lecture. http://nobelprize.org/nobel_prizes/chemistry/laureates/1972/anfinsen-lecture.pdf
20. Levinthal C. Are there pathways for protein folding? [J]. Extrait du J de Chimie Physique, 1968,65(1):44-45.
21. Dill KA, Chan HS. From Levinthal to pathways to funnels [J]. Nat Struct Biol, 1997,4(1):10-19.
22. Creighton TE. Toward a better understanding of protein folding pathways [J]. Proc Nat Acad Sci USA, 1988,85(14):5082-5086.
23. Chang IJ, Lee JC, Winkler JR, et al. The protein-folding speed limit: intrachain diffusion times set by electron-transfer rates in denatured Ru(NH3)5(His-33)-Zn -cy tochrome c [J]. Proc Nat Acad Sci USA, 2003,100(7):3838-3840.
24. Dill KA, Ozkan SB, Shell MS, et al. The protein folding problem [J]. Annu Rev Biophys, 2008,37:289-316.
25. Milton RC, Milton SC, Kent SB. Total chemical synthesis of a D-enzyme: the enantiomers of HIV-1 protease show reciprocal chiral substrate specificity [J]. Science, 1992, 256(5062):1445-1448.
26. Hartl FU, Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein [J]. Science, 2002,295 (5561): 1852-1858.
27. Gething MJ, Sambrook J. Protein folding in the cell [J]. Nature, 1992, 355(6355):33-45.
28. Lindquist (McKenzie) S, Henikoff S, Meselson M. Localization of RNA from heat-induced polysomes at puff sites in Drosophila melanogaster [J]. Proc Natl Acad Sci USA, 1975,72(3):1117-1121.
29. Pelham HRB. Speculations on the functions of the major heat shock and glucose-regulated proteins [J]. Cell, 1986,46(7):959-961.
30. Ellis J. Proteins as molecular chaperones [J]. Nature, 1987,328 (6129):378-379.
31. Jakob U, Gaestel M, Engel K, et al. Small heat shock proteins are molecular chaperones [J]. J Biol Chem, 1993,268(3):1517-1521.
32. Glover JR, Tkach JM. Crowbars and ratchets: hsp100 chaperones as tools in reversing protein aggregation [J]. Biochem Cell Biol, 2001,79(5):557-568.
33. Sliutz G, Karlseder J, Tempfer C, et al. Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy [J]. Br J Cancer, 1996,74(2):172-177.
34. Glover JR, Lindquist S. Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins [J]. Cell, 1998,94(1):73-82.
35. Lu S, Tan Z, Wortman M, et al. Regulation of heat shock protein 70-1 expression by androgen receptor and its signaling in human prostate cancer cells [J]. Int J Oncol, 2010,36(2):459-467.
36. Pelham HRB. The dynamic organisation of the secretory pathway [J]. Cell Str Function, 1996,21(5):413-419.
37. Ciechanover A, Hod Y, Hershko A. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes [J]. Biochem Biophys Res Comm, 1978,81(4):1100-1105.
38. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. 2004 Nobel Lecture, http://nobelprize.org/nobel_prizes/chemistry/laureates/2004/ciechanover-lecture.html.
39. Hersko A. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. 2004 Nobel Lecture, http://nobelprize.org/nobel_prizes/chemistry/laureates/2004/hershko-lecture.html.
40. Rose I. Ubiquitin at Fox Chase. 2004 Nobel Lecture, http://nobelprize.org/nobel_prizes/chemistry/laureates/2004/rose-lecture.html.
41. Tanaka K. The proteasome: overview of structure and functions [J]. Proc Jpn Acad, 2009,85(1):12-36.
42. Yang Y, Kitagaki J, Wang H, et al. Targeting the ubiquitin-proteasome system for cancer therapy [J]. Cancer Sei, 2009,100 (1):24-28.
43. Min JH, Yang H, Ivan M, et al. Structure of an HIF-lalpha -pVHL complex: hydroxyproline recognition in signaling [J]. Science, 2002,296(5574): 1886-1889.
44. McClellan AJ, Scott MD, Frydman J. Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways [J]. Cell, 2005,121(5):739-748.
45. Stratton MR, Campbell PJ, Futreal PA. The cancer genome [J]. Nature, 2009,458(7239):719-724.
46. Whitesell L, Mimnaugh EG, deCosta B, et al. Inhibition of heat shock protein HSP90-pp 60v-sr c heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation [J]. Proc Natl Acad Sei USA, 1994,91 (18):8324-8328.
47. Pacey S, Banerji U, Judson I, et al. Hsp90 inhibitors in the clinic [J]. Hand Exp Pharmacol, 2006,2006(172):331-358.
48. Workman P, Burrows F, Neckers L, et al. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress [J]. Ann NY Acad Sei, 2007, 1113:202-216.
49. Whitesell L, Bagatell R, Falsey R. The stress response: implications for the clinical development of hsp90 inhibitors [J]. Curr Cancer Drug Targets, 2003,3(5):349-358.
50. Picard D. 2009, http://www.picard.ch/downloads/Hsp90interactors.pdf.
51. Jolly C, Morimoto RL. Role of the heat shock response and molecular chaperones in oncogenesis and cell death [J]. J Natl Cancer Inst, 2000,92(19):1564.
52. Munster PN, Basso A, Solit D, et al. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner [J]. Clin Cancer Res, 2001,7(8)2155-2158.
53. Nylandsted J, Rohde M, Brand K, et al. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2 [J]. Proc Nat Acad Sei USA, 2000,97(14):7871-7876.
54. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-m olecule antagonists of MDM2 [J]. Science, 2004,303(5659):844-848.
55. Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer [J]. Nature, 2009,458(7239):732-736.
56. O'Dwyer ME, Druker BJ. STI571: an inhibitor of the BCR-A BL tyrosine kinase for the treatment of chronic myelogenous leukaemia [J]. Lancet Oncol, 2000,1:207-211.
57. Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? [J]. Nat Rev Cancer, 2007,6(2):115-120.
58. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? [J]. Nat Rev Drug Discov, 2004,3(8):711-715.
59. Xu Z, Horwich AL, Sigler PB. The crystal structure of the asymmetric GroEL-G roES-(A DP)7 chaperonin complex [J]. Nature, 1997,388(6644):741-750.
60. Pearl LH, Prodromou C. Structure and Mechanism of the Hsp90 molecular chaperone machinery [J]. Ann Rev Bioch, 2006,75: 271-294.
61. Weinberg RA. The biology of cancer [M]. New York: Garland Science, 2007:244.